Objectives: This study sought to compare paclitaxel-eluting balloon (PEB) with conventional
percutaneous transluminal angioplasty (PTA), followed by systematic implantation of a self …

Background: While randomized trials have demonstrated the superiority of drug-coated
balloon (DCB) angioplasty versus standard percutaneous transluminal angioplasty (PTA) in …

Background Paclitaxel‐eluting balloon (PEB) angioplasty has superior efficacy compared
with conventional balloon angioplasty (BA) for de novo lesions of superficial femoral artery …

Background: Evidence from large, randomized, controlled peripheral artery disease trials
reporting long-term outcomes using drug-coated balloons (DCBs) is limited. Previously, the …

Background—Randomized controlled trials have reported favorable 1-year outcomes with
drug-coated balloons (DCBs) for the treatment of symptomatic peripheral arterial disease …

Objectives To assess the longer‐term safety and efficacy of the IN. PACT Admiral (MDT‐
2113) drug‐coated balloon (DCB) for the treatment of de novo and non‐stented restenotic …

Background—Drug-coated balloons (DCBs) have shown promise in improving the
outcomes for patients with peripheral artery disease. We compared a paclitaxel-coated …

Objectives: The authors sought to evaluate the performance of the Ranger paclitaxel-coated
balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months …

Background: Numerous studies have reported favorable outcomes using drug-coated
balloons (DCBs) for treatment of symptomatic peripheral artery disease of the superficial …

Purpose: To assess the safety and effectiveness of the MDT-2113 (IN. PACT Admiral) drug-
coated balloon (DCB) for the treatment of de novo and native artery restenotic lesions in the …